Metformin: are potential benefits on cancer risk extended to cancer survival?
作者信息
La Vecchia Carlo, Bosetti Cristina
机构信息
Department of Epidemiology, IRCCS-lstituto di Ricerche Farmacologiche Mario Negri, Milano, Italy;
出版信息
Oncologist. 2013;18(12):1245-7. doi: 10.1634/theoncologist.2013-0381. Epub 2013 Nov 20.
Abstract
摘要
相似文献
1
Metformin: are potential benefits on cancer risk extended to cancer survival?
Oncologist. 2013;18(12):1245-7. doi: 10.1634/theoncologist.2013-0381. Epub 2013 Nov 20.
2
Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.
Oncologist. 2013;18(12):1248-55. doi: 10.1634/theoncologist.2013-0111. Epub 2013 Nov 20.
3
The effect of metformin on mortality following cancer among patients with diabetes.
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1974-84. doi: 10.1158/1055-9965.EPI-14-0327. Epub 2014 Jul 16.
4
[Metformin can reduce the risk of colorectal cancer].
Ugeskr Laeger. 2015 May 18;177(21):V12140659.
5
Metformin and colorectal cancer risk in diabetic patients.
Diabetes Care. 2011 Oct;34(10):2336-7. doi: 10.2337/dc11-1447.
6
Association between pancreatic cancer and metformin use in patients with type 2 diabetes.
Postgrad Med J. 2019 May;95(1123):291. doi: 10.1136/postgradmedj-2019-136463. Epub 2019 Apr 11.
7
Commentary: metformin use is associated with reduced gastric cancer risk.
Aliment Pharmacol Ther. 2014 May;39(10):1239. doi: 10.1111/apt.12723.
8
Gastric cancer. Metformin improves survival and recurrence rate in patients with diabetes and gastric cancer.
Nat Rev Gastroenterol Hepatol. 2015 Mar;12(3):124. doi: 10.1038/nrgastro.2015.9. Epub 2015 Jan 27.
9
Metformin and the incidence of cancer in patients with diabetes: a nested case-control study.
Diabetes Care. 2013 Sep;36(9):e155-6. doi: 10.2337/dc13-0708.
10
Metformin Use and Lung Cancer Risk--Letter.
Cancer Prev Res (Phila). 2015 Aug;8(8):760. doi: 10.1158/1940-6207.CAPR-15-0075. Epub 2015 May 19.
本文引用的文献
1
Building reliable evidence from real-world data: Needs, methods, cautiousness and recommendations.
Pulm Pharmacol Ther. 2018 Dec;53:61-67. doi: 10.1016/j.pupt.2018.09.009. Epub 2018 Sep 22.
2
Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis.
Oncologist. 2013;18(12):1248-55. doi: 10.1634/theoncologist.2013-0111. Epub 2013 Nov 20.
3
Increased risk of cognitive impairment in patients with diabetes is associated with metformin.
Diabetes Care. 2013 Oct;36(10):2981-7. doi: 10.2337/dc13-0229. Epub 2013 Sep 5.
4
Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study.
Neurology. 2013 Jul 23;81(4):322-8. doi: 10.1212/WNL.0b013e31829c5ec1. Epub 2013 Jul 10.
5
Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.
Oncologist. 2013;18(2):148-56. doi: 10.1634/theoncologist.2012-0302. Epub 2013 Jan 23.
6
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.
Nature. 2013 Feb 14;494(7436):256-60. doi: 10.1038/nature11808. Epub 2013 Jan 6.
7
Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
PLoS One. 2012;7(12):e51814. doi: 10.1371/journal.pone.0051814. Epub 2012 Dec 19.
8
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.
Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):972-7. doi: 10.1073/pnas.1221055110. Epub 2012 Dec 31.
9
Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel.
Biochem Pharmacol. 2013 Feb 15;85(4):583-94. doi: 10.1016/j.bcp.2012.12.001. Epub 2012 Dec 7.
10
Diabetes and breast cancer risk: a meta-analysis.
Br J Cancer. 2012 Oct 23;107(9):1608-17. doi: 10.1038/bjc.2012.414. Epub 2012 Sep 20.
Zotero 插件